drugset / Trial / NCT04026100
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1
Unknown
9 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Bioheng Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.
Timeline
- Start
- 2019-12-01
- Primary completion
- 2022-08-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTA101 | Cell therapy | 200000 cells | Intravenous |
| Subject | CTA101 | Cell therapy | 2e+06 cells | Intravenous |
| Subject | CTA101 | Cell therapy | 3e+06 cells | Intravenous |